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http://dx.doi.org/10.1016/j.ccell.2016.06.004SUMMARYPIK3CA, which encodes the p110a subunit of PI3K, is frequently mutated and oncogenic in breast cancer.
PI3Ka inhibitors are in clinical development and despite promising early clinical activity, intrinsic resistance
is frequent among patients. We have previously reported that residual downstream mTORC1 activity upon
treatment with PI3Ka inhibitors drives resistance to these agents. However, the mechanism underlying
this phenotype is not fully understood. Here we show that in cancer cells resistant to PI3Ka inhibition,
PDK1 blockade restores sensitivity to these therapies. SGK1, which is activated by PDK1, contributes to
the maintenance of residual mTORC1 activity through direct phosphorylation and inhibition of TSC2. Target-
ing either PDK1 or SGK1 prevents mTORC1 activation, restoring the antitumoral effects of PI3Ka inhibition in
resistant cells.INTRODUCTION
The phosphoinositide 3-kinase (PI3K) pathway integrates many
extracellular stimuli and triggers the phosphorylation of key
downstream effectors such as AKT and the mammalian Target
of Rapamycin Complex 1 and 2 (mTORC1 and 2). This sig-
naling cascade is essential for regulating cell size, proliferation,
survival, and metabolism (Engelman, 2009; Thorpe et al.,
2015). Activation of PI3K results in increased phosphatidylino-
sitol-(3,4,5)-triphosphate (PIP3) at the plasma membrane, pro-
moting the recruitment of the pleckstrin homology (PH)Significance
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nase PDK1 phosphorylates AKT at the activation loop (T308)
(Alessi et al., 1997) and mTORC2 in the hydrophobic motif
(S473) (Sarbassov et al., 2005). Once active, AKT phosphory-
lates a variety of antiapoptotic and cell-cycle-related proteins
as well as transcription factors (Manning and Cantley, 2007).
Moreover, AKT activates downstream mTORC1 through the
phosphorylation of the negative regulators TSC2 and PRAS40
(Inoki et al., 2002; Manning et al., 2002; Potter et al., 2002;
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Activating mutations in PIK3CA, which encodes the a isoform
of the p110 catalytic subunit of PI3K, results in hyperactivation of
the PI3K/AKT/mTOR pathway (Engelman, 2009). These muta-
tions are common in breast cancer and provide the rationale
for the development of inhibitors targeting the different nodes
of the PI3K pathway (Fruman and Rommel, 2014).
PI3Ka-specific inhibitors are showing promising results in pa-
tients with tumors bearing activating PIK3CA mutations, but not
all such tumors are sensitive (Juric et al., 2012, 2013). Under-
standing the molecular mechanisms by which tumors bypass
the pharmacological inactivation of PI3Ka is crucial for the iden-
tification of patientsmore likely to respond to these inhibitors and
for devising therapeutic strategies to improve the clinical benefit.
We previously reported that the activation status of mTORC1
upon PI3Ka blockade is a determinant of drug sensitivity in
PIK3CA-mutant tumors. Despite full inhibition of PI3K/AKT, the
presence of residual mTORC1 activity is sufficient to weaken
the antitumor activity of PI3Ka inhibition. Resistant tumors are
sensitized by co-treatment with the mTORC1 allosteric inhibitor
everolimus, underscoring the causative role of mTORC1 in
limiting the effects of PI3Ka blockade (Elkabets et al., 2013). In
this work, we elucidate the molecular pathway that allows
mTORC1 to retain activity in the presence of PI3K and AKT
inactivation.
RESULTS
PDK1 Inhibition Sensitizes Resistant Cells to BYL719
Aiming to identify possible kinases or phosphatases respon-
sible for the AKT-independent sustained mTORC1 activity in
cells resistant to PI3Ka inhibition, we performed a small inter-
fering RNA (siRNA) screen using a library targeting 710 kinases
and 298 phosphatases encoded in the human genome. We
measured cell viability and S6 ribosomal protein (S6) phosphor-
ylation, a bona fide readout of mTORC1 activity, in the presence
of BY719, a PI3Ka-specific inhibitor.
The screen design is shown in Figure S1A. Three different
siRNAs targeting each member of the kinome/phosphatome
were transfected in JIMT1 and HCC1954 cell lines, both of which
are PIK3CA mutant and insensitive to BYL719. After treatment
over 6 days, we found that knockdown of 37 enzymes in
HCC1954 and 35 enzymes in JIMT1 sensitized cells to PI3Ka in-
hibition (Figure S1B and Table S1). Among these, five were found
to be shared in both cell lines: MTOR, PDPK1, PIK3CA,
PPP1R12A, and PAPL (Figure S1B). These findings were vali-
dated with a second targeted screening using the two most
active siRNAs against each of these five targets, interrogating
for both cell viability and phosphorylation of S6. With this more
stringent approach, we found that only knockdowns of mTOR
and PDK1 were capable of reducing S6 phosphorylation
(S240/4) in the presence of PI3Ka inhibition (Figure S1C). While
the finding of mTOR confirmed our previous data (Elkabets
et al., 2013), the contribution of PDK1 in maintaining the resistant
phenotype was an original finding.
PDK1 is a kinase that belongs to the Containing PKA, PKG,
and PKC (AGC) kinase family that includes AKT, PKC, RSK,
SGK, and S6K (Pearce et al., 2010). To confirm that PDK1 limits
the sensitivity to PI3Ka inhibition bymaintainingmTORC1 activ-
ity upon PI3Ka inhibition, we generated HCC1954 and JIMT1230 Cancer Cell 30, 229–242, August 8, 2016cell lines stably expressing a PDK1 short hairpin RNA (shRNA).
We observed that PDK1 knockdown is sufficient to decrease
cell viability upon BYL719 treatment (Figures 1A and S2A). As
previously described, treatment with BYL719 alone reduced
AKT phosphorylation (S473 and T308) but not downstream
mTORC1 targets (Elkabets et al., 2013). In contrast, the combi-
nation of PDK1 knockdown with BYL719 decreased the phos-
phorylation of the mTORC1 downstream targets p70 S6 kinase
(S6K) and translation initiation factor 4E-binding protein
(4EBP1), as well as phosphorylated S6 at both S240/4 and
S235/6 sites (Figures 1B and S2B). As a result, the combination
of BYL719 and PDK1 knockdown decreased cap-dependent
translation (Figure S2C), a cellular process directly regulated
by mTORC1 (Silvera et al., 2010). In PDK1 knockdown cells, in-
hibition of PI3Ka induced an increased binding of 4EBP1 to the
cap m7GpppN mRNA analog m7GTP, to a similar extent as the
mTOR kinase inhibitor AZD8055. On the contrary, we observed
a reduction of the eukaryotic initiation factors (eIF) eIF4G and
eIF4A, components of the eIF4F cap-initiation complex. As ex-
pected, eIF4E remained unchanged. In long-term treatments,
the combination of BYL719 and PDK1 knockdown induced pol-
y(ADP-ribose)polymerase (PARP) cleavage (Figure 1C) and
increased caspase 3/7 activity (Figure 1D), surrogate markers
of apoptotic activity.
Pharmacological inhibition of PI3Ka resulted in amodest delay
in tumor growth in shGFP control xenografts but was sufficient to
induce durable tumor shrinkage in tumors with ablated PDK1
(Figure 1E). Analysis of the tumors showed that BYL719 treat-
ment effectively suppressed AKT phosphorylation (S473) in
both shGFP and shPDK1 tumors, whereas S6 and 4EBP1 phos-
phorylation was inhibited only in shPDK1 xenografts (Figures 1F
and S2D).
Next, we tested the activity of BYL719 in combination with
GSK2334470, a highly selective PDK1 inhibitor (Najafov et al.,
2011). We determined the appropriate dose of GSK2334470 to
be used in combination with PI3Ka inhibition by analyzing both
phosphorylation of the PDK1 target RSK2 (S227) and cell viability
upon incubation with increasing concentrations of the PDK1
inhibitor. At 1 mM, pRSK2 (S227) was appreciably reduced
(Figure S2E) with no significant changes in cell viability (Fig-
ure S2F). Despite the minimal effect on cell viability when used
as a single agent, treatment with GSK2334470 was sufficient
to sensitize both HCC1954 and JIMT1 cells and the triple-nega-
tive BYL719-resistant breast cancer cell line BT20 to PI3Ka inhi-
bition (Figures 1G and S2G–S2H). Again, we observed that only
the combination of BYL719 and GSK2334470 resulted in the in-
hibition of AKT and mTORC1 (Figures 1H, S2I, and S2J). Some
residual pS6 was observed in BT20 cells, which might be attrib-
uted to the heterogeneity of the cell line or additional mecha-
nisms that regulate S6 phosphorylation.
PDK1 inhibition did not decrease the phosphorylation of AKT
at the activation loop (T308) as a result of a compensatory mech-
anism involving PIP3 and mTORC2, an observation in line with
previous reports (Najafov et al., 2012). Analysis of cap-depen-
dent translation complex formation revealed an increase in
4EBP1 and a decrease in eIF4G and eIF4A in m7GTP pulldowns
when both drugs were combined, consistent with mTORC1 inhi-
bition (Figure S2K). Consistent with the knockdown experiments,
the combination of BYL719 andGSK2334470 induced apoptosis
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Figure 1. PDK1 Inhibition Sensitizes Resistant Cells to BYL719
(A) Dose-response curves from HCC1954 cells transduced with shGFP and shPDK1 and treated with BYL719 for 6 days.
(B) Western blot comparing cells from (A) treated with BYL719 (1 mM) for 4 hr.
(C) PARP western blot in cells transduced with shGFP and shPDK1 and treated with BYL719 (1 mM) for 24 hr.
(D) Caspase 3/7 DEVDase activity of HCC1954 shGFP and shPDK1 cells treated with BYL719 (1 mM) for 12 hr in the presence or absence of caspase inhibitor
zVAD-fmk (20 mM). Staurosporine was used as a positive control (1 mM; 4 hr).
(E) HCC1954 shGFP and shPDK1 xenografts treated with vehicle or BYL719 (n = 10/arm).
(F) IHC analysis of tumors from (E) collected at the end of the experiment after 4 hr of the last treatment. Scale bar, 100 mm.
(G) Dose-response curves from HCC1954 cells treated with BYL719 in the presence or absence of GSK2334470 (1 mM) over 6 days.
(H) Western blot comparing HCC1954 cells treated with BYL719 (1 mM), GSK2334470 (1 mM), or the combination of both agents for 4 hr.
(I) Western blot of PARP in cells treated for 24 hr.
(J) Caspase 3/7 DEVDase activity of lysates from HCC1954 cells treated with BYL719 (1 mM), GSK2334470 (1 mM), or the combination of both agents for 12 hr in
the presence or absence of caspase inhibitor zVAD-fmk (20 mM). Staurosporine was used as a positive control (1 mM, 4 hr).
(K) HCC1954 xenografts treated with vehicle, BYL719 (25 mg kg1), GSK2334470 (100 mg kg1), or the combination of both agents (n = 10/arm).
(L) IHC analysis of tumors from (K) collected at the end of the experiment after 4 hr of the last treatment. Scale bar, 100 mm.
p Values were calculated using Student’s t test. Error bars denote ±SEM. See also Figures S1 and S2.in HCC1954 cells when measured by PARP cleavage (Figure 1I)
and caspase 3/7 activity (Figure 1J).
We then expanded our results in vivo. Although some anti-
tumor activity was observed with treatment with BYL719 or
GSK2334470, only the combination of both compounds induced
durable tumor shrinkage (Figure 1K) and inhibition of pAKT (S473),
pS6 (S240/4), and p4EBP1 (T37/46) (Figures 1L and S2L–S2O).Taken together, these results indicate that PDK1 inhibition
sensitizes cells to PI3Ka blockade via suppression of mTORC1.
The PIF-Binding Pocket of PDK1 Is Required for
Sustained mTORC1 Activation upon PI3Ka Inhibition
The activation of AGC kinases requires phosphorylation at two
highly conserved regulatory motifs termed the hydrophobicCancer Cell 30, 229–242, August 8, 2016 231
motif (HM) and the activation loop. Several kinases prime AGC
kinases for activation through phosphorylation at the HM.
PDK1, which acts as a master regulator of this family of kinases,
scaffolds at the phosphorylated HM using the PIF (PDK1-inter-
acting fragment) binding pocket. This interaction enables phos-
phorylation of the activation loop, thereby fully activating their
activity. However, AKT does not require the PIF-binding pocket
of PDK1 but instead needs its PH domain to interact with
PDK1 at the plasma membrane in a PIP3-dependent manner
(Alessi et al., 1997; Arencibia et al., 2013; Biondi et al., 2001;
Collins et al., 2003; McManus et al., 2004). To explore the
PDK1 regulatory mechanism required to sustain mTORC1 activ-
ity upon PI3Ka inhibition, we used the HCT116 parental and
PDPK1-null (PDPK1/) isogenic model (Ericson et al., 2010).
HCT116 cells harbor the H1047R PIK3CA-activating mutation,
and the addition of BYL719 decreased AKT phosphorylation
but did not decrease mTORC1 signaling, mimicking the pheno-
type observed in BYL719-resistant breast cancer cell lines. How-
ever, in PDPK1/ cells, the addition of BYL719 inhibited
mTORC1 (Figure S2P).
We reconstituted HCT116 PDPK1/ cells with the wild-type
(WT), kinase-inactive K111N (KD), PIP3-binding deficient
K546E (KE), and PIF-pocket-deficient L155E (LE) mutants (Fig-
ure S2Q) to test the contribution of each regulatory mechanism
of PDK1 to mTORC1 activation. Reconstitution of PDK1 WT,
but not the mutant KD, restored mTORC1 activation in the pres-
ence of BYL719. The mutant KE was also able to restore the
phenotype. On the other hand, the mutant LE was unable to
rescue mTORC1 signaling (Figure S2R). This set of experiments
suggests that themaintenance ofmTORC1 activity requires both
kinase activity and the PIF-binding pocket of PDK1 but is PIP3-
and, consequently, AKT-independent.
Combined Suppression of PI3Ka and PDK1 Activates
FOXO-Dependent Transcription
We next performed gene-expression analysis to investigate
whether mTORC1 suppression is accompanied by specific tran-
scriptional changes. While the differences in gene expression
upon BYL719 or GSK2334470 treatment were modest, the com-
bination of both induced marked changes when compared with
the DMSO-treated control cells (Figures 2A and S3A). Gene set
enrichment analysis of these data showed enrichment of
FOXO3 transcription factor targets in both cell lines (Figures 2B
and S3B). Individual genes described to be positively (CCNG2,
BCL6, IRS2) or negatively (CCND1) regulated by FOXO3
(Webb and Brunet, 2014) were confirmed to be induced or
repressed, respectively, upon dual PI3Ka and PDK1 blockade
(Figure 2C). These results were further validated by performing
qRT-PCR of four well-described FOXO3 targets, ERBB3,
TNFSF10, BCL6, and IRS2 (Webb and Brunet, 2014), following
different treatments (Figures 2D and S3C).
Upon growth factor stimulation, FOXO transcription factors
are phosphorylated at several residues and retained in the
cytosol by the 14-3-3 proteins (Webb and Brunet, 2014). Inhibi-
tion of these mitogenic signals induces a rapid dephosphoryla-
tion and nuclear translocation of FOXOs that allows expression
of downstream target genes involved in apoptosis and/or cell-
cycle arrest (Webb and Brunet, 2014). In our cells, we found
that treatment with both BYL719 and GSK2334470, but not232 Cancer Cell 30, 229–242, August 8, 2016either single agent, resulted in strong nuclear localization of
FOXO3 (Figures 2E and S3D). This was consistent with a
decreased phosphorylation of this transcription factor at residue
T32 (Figure 2F). Moreover, we observed that only the combina-
tion stimulated endogenous FOXO transcriptional activity (Fig-
ure 2G) and increased occupancy of FOXO3A at the promoters
of two well-known FOXO targets, IRS2 and TNFSF10 (Figures
2H and S3E). These results suggest that dual PI3Ka and PDK1
inhibition induces a FOXO-dependent transcriptional activity in
BYL719-resistant cells.
SGK1 IsUpregulated in BYL719-ResistantCell Lines and
in Tumors from Patients Refractory to PI3Ka Inhibition
AKT has been shown to phosphorylate FOXO1 and FOXO3 at
T24 and T32 residues, respectively (Brunet et al., 1999). How-
ever, we observed that despite full inhibition of AKT by PI3Ka
inhibition, FOXO3was not efficiently primed to migrate to the nu-
cleus and exert its transcriptional activity in cells resistant to
BYL719 (Figures 2 and S3). Since PDK1 requires downstream
AGC kinases as molecular effectors (Pearce et al., 2010), we
reasoned that in BYL719-resistant cells a downstream AGC ki-
nase dependent on the PDK1 catalytic activity and docking
with the PIF-binding pocket (Figure S2R) regulates both
FOXO1/3 phosphorylation and mTORC1 activity, independently
of AKT.
Serum and glucocorticoid-induced kinase (SGK) is a family of
AGC serine/threonine kinases that comprises three members
(SGK1–3) highly homologous to AKT (Kobayashi and Cohen,
1999). SGK1 activation is mediated by mTORC2-dependent
phosphorylation at the HM (S422) and subsequent PDK1 phos-
phorylation at the activation loop (T256) in a PIF-binding
pocket-dependent manner (Garcia-Martinez and Alessi, 2008;
Pearce et al., 2010). Earlier reports have demonstrated that
SGK1 is able to directly phosphorylate FOXO1 at residues T32
andS315 (Brunet et al., 2001) and has been correlatedwith resis-
tance to AKT inhibition (Sommer et al., 2013). Therefore, we hy-
pothesized that SGK1 plays a critical role downstream of PDK1
in sustaining mTORC1 activity and inducing resistance to PI3Ka
inhibition.
We analyzed the basal mRNA expression of 27 breast cancer
cell lines, previously characterized as sensitive or resistant to
BYL719 (Elkabets et al., 2013), and found that resistant cell lines
had significantly higher levels of SGK1 mRNA compared with
sensitive cells (Figures 3A and S4A). This held true when only
breast cancer cells harboring PIK3CA-activating mutations,
which are known to be sensitive to PI3Ka inhibition (Elkabets
et al., 2013), were considered in the analysis (Figures 3B and
3C). The mRNA levels of SGK2 and SGK3 were similar between
sensitive and resistant cell lines (Figure S4B), although JIMT1
cells also express high levels of SGK2. The ratio of phosphory-
lated N-Myc Downstream Regulated 1 (NDRG1) (T346), a sub-
strate of SGK1 (Murray et al., 2004), versus total NDRG1 was
also higher in BYL719-resistant cells (Figures 3C and S4C).
Both CAL-148 and CAL-51 cells carry mutations in PTEN (Ce-
rami et al., 2012), and their resistance to BYL719 may be due
to insufficient inhibition of the PI3K/AKT pathway as a conse-
quence of PI3Kb activity (Juric et al., 2015). However, BYL719,
but not the PI3Kb inhibitor AZD6482, fully decreases pAKT levels
in both CAL-148 and CAL-51 cells (Figure S4D).
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Figure 2. FOXO Activation upon PDK1 and PI3Ka Inhibition
(A) Changes in the top 200 differentially expressed genes in HCC1954 and JIMT1 cells treated with DMSO, BYL719 (1 mM), GSK2334470 (1 mM), or the com-
bination of both agents for 4 hr. Gene upregulation is in red and gene downregulation is in green.
(B) Enrichment plot for the FOXO3 signature in HCC1954 cells. NES, normalized enrichment score.
(C) Heatmap showing changes in expression of FOXO3 targets in HCC1954 and JIMT1 cells.
(D) mRNA expression in HCC1954 cells treated with DMSO, BYL719 (1 mM), GSK2334470 (1 mM), or the combination of both agents for 4 hr.
(E) Representative images of FOXO3 immunofluorescence (green) in HCC1954 cells treated with DMSO, BYL719 (1 mM), GSK2334470 (1 mM), or the combination
of both agents for 4 hr. Nuclei are shown in blue (DAPI). Scale bar, 25 mm.
(F) Western blot analysis of FOXO1/3 phosphorylation (T24/T32) in HCC1954 and JIMT1 cells treated with DMSO, BYL719 (1 mM), GSK2334470 (1 mM), or the
combination of both agents for 4 hr.
(G) Luciferase reporter assay in HCC1954 cells stably transduced with the FOXO consensus motif reporter construct treated as indicated for 12 hr. RLU, relative
light units.
(H) ChIP-qPCR assay of FOXO3A binding at TNFSF10A and IRS2 promoters in HCC1954 cells treated as indicated in (F).
p Values were calculated using Student’s t test. Error bars denote ±SEM. See also Figure S3.Given the lack of reliable results obtained with commercially
available antibodies against SGK1, we analyzed the expres-
sion of pNDRG1 (T346) in 273 breast invasive carcinomas,
comprising 138 triple-negative breast cancer (TNBC), 68 estro-
gen-/progesterone-receptor-positive, and 67 human epidermal
growth factor 2 (HER2)-positive breast cancer patients. High
pNDRG1 staining was found in TNBC (21%) and HER2-positive
tumors (12%) (Figure 3D), a finding in line with the percentage of
breast cancer samples expressing high levels of SGK1 in the
Cancer Genome Atlas cohort (Ciriello et al., 2015).We then explored whether SGK1 and pNDRG1 expression
correlate with clinical outcome to PI3Ka inhibition by analyzing
PIK3CA-mutant breast cancer samples from 18 patients treated
with BYL719 in combination with an aromatase inhibitor
(NCT01870505). Three of these tumors expressed high levels
of SGK1mRNA while the remaining 15 had medium to low levels
of SGK1 mRNA. The three patients with tumors exhibiting high
SGK1 expression, which also stained positive for pNDRG1, did
not respond to therapy (Figures 3E and 3F). Two patients with tu-
mors expressing medium to low levels of SGK1 stained positiveCancer Cell 30, 229–242, August 8, 2016 233
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for pNDRG1 and rapidly progressed. On the contrary, in the
group of patients with pNDRG1-negative tumors, three had par-
tial responses and eight had stable disease by RECIST
(response evaluation in solid tumors) criteria (Therasse et al.,
2000). This was in agreement with the longer time to disease
progression of this subset of patients when compared with
the SGK1-high/pNDRG1-positive cohort (Figures 3E and 3F).
Although suggestive of a role of SGK1 in mediating intrinsic
resistance to PI3Ka inhibitors, these results should be validated
in larger cohorts of patients.
We then sought to investigate the mechanism underlying
this variability in SGK1 expression. We analyzed the promoter
of SGK1 and realized that in the region between 56 bp
and +391 bp of the transcription start site there are 12 CpG sites
that are susceptible for DNA methylation. Using bisulfite
sequencingwe found that three of theseCpG siteswere differen-
tially methylated between sensitive and resistant cell lines (Fig-
ure S4E). We confirmed our results quantitatively using direct py-
rosequencing in 11 cell lines (8 sensitive and 3 resistant to PI3Ka
inhibition). Sensitive cell lines exhibited high levels of SGK1 pro-
moter methylation (mean CpG1 = 65%, CpG2 = 67%, and
CpG3 = 40%), while resistant cell lines displayed low levels of
SGK1 promoter methylation (mean CpG1 = 11%, CpG2 = 13%,
and CpG3 = 16%) (Figure S4F). The degree of promoter DNA
methylation inversely correlated withSGK1mRNA levels in these
cells (Figure S4G). By chromatin immunoprecipitation (ChIP)-
qPCR assays, we found high occupancy of RNA polymerase II
(Pol II), an enzyme essential for transcription, and phosphory-
lated (S5) Pol II in both HCC1954 and JIMT1 cells, indicating
that SGK1 transcription is active in these resistant cell lines
(Figure S4H). On the contrary, in the sensitive cell lines MDA-
MB-453 and T47D we found low occupancy of both Pol II and
phosphorylated Pol II (S5) in the SGK1 promoter (Figure S4H).
Treatment with the DNA demethylating agent 5-Aza-20-deoxycy-
tidine and the histone deacetylase inhibitor panobinostat re-
duced SGK1 promoter DNA methylation (data not shown) and
increased mRNA levels of SGK1 in the four sensitive cell lines
tested (Figure S4I). Our results indicate that the differential
expression of SGK1 is mediated, at least in part, by epigenetic
regulation.
Although pNDRG1 and SGK1 expression correlates in vivo
(Murray et al., 2004), AKT can also phosphorylate NDRG1 inFigure 3. SGK1 Upregulation in BYL719-Resistant Cell Lines
(A) SGK1 mRNA levels in breast cancer cell lines sensitive or resistant to BYL71
represent minimum and maximum.
(B) SGK1 mRNA levels in a panel of PIK3CA-mutant breast cancer cell lines sen
(C) Western blot analysis of SGK1, SGK2, SGK3, and phosphorylated NDRG1 in
SGK1 isoforms.
(D) Representative images of phosphorylated NDRG1 (T346) IHC in breast cance
cancer cases.
(E) Summary of the median number of days of progression-free survival (PFS) a
response according to RECIST criteria in association with SGK1 mRNA levels an
(F) Waterfall plot showing changes in tumor size of the patients included in the s
(G) Western blot for NDRG1 and phosphorylated NDRG1 (T346) in BYL719-sens
(H)Western blot of phosphorylated NDRG1 (T346) in resistant cells treatedwith DM
4 hr.
(I) Endogenous kinase assay for SGK1 and AKT in HCC1954 cells treated with DM
4 hr.
p Values were calculated using Student’s t test. Error bars denote ±SEM. See althe absence of SGK1 in cultured cell lines (Sommer et al.,
2013). In support of these observations, cancer cells sensitive
to BYL719 displayed decreased NDRG1 phosphorylation at
T346 when treated with BYL719 (Figure 3G). In contrast, resis-
tant cell lines treated with BYL719 maintain NDRG1 phosphory-
lation, underscoring the role of SGK1 in this setting. Central to
our work, only the combination of BYL719 and GSK2334470
was able to decrease the phosphorylation of NDRG1 in
BYL719-resistant cell lines, confirming that the combination of
both drugs is required to effectively inhibit both SGK1 and AKT
activity (Figure 3H).
Next, we immunoprecipitated endogenous SGK1 and found
that BYL719 treatment was not sufficient to completely abolish
the kinase activity of the enzyme, in contrast to GSK2334470
(Figure 3I). On the other hand, immunoprecipitation of endoge-
nous AKT revealed that while BYL719 treatment completely
abrogated AKT kinase activity, this is not the case when cells
are treated with GSK2334470, as previously observed (Najafov
et al., 2012). This is indicative of a signaling compensation be-
tween AKT and SGK1 and that only the combination of PI3Ka
and PDK1 inhibitors can simultaneously block the activity of
the endogenous enzymes in resistant cells. While mTORC2-
mediated phosphorylation at the HM is indispensable for SGK1
kinase activity (Kobayashi and Cohen, 1999), several reports
indicate that AKT remains active in the absence of HMphosphor-
ylation, as phosphorylation at the activation loop (T308) is suffi-
cient to partially activate the kinase (Guertin et al., 2006; Jacinto
et al., 2006; Rodrik-Outmezguine et al., 2011). Treatment of
HCC1954 cells with the mTOR catalytic inhibitor AZD8055,
which targets both mTORC1 and mTORC2 and completely in-
hibits SGK1 but not AKT activity, did not reduce the levels of
the substrates pFOXO3 (T32) and pNDRG1 (T346), confirming
that mTORC2 inhibition is not sufficient to abolish AKT activity
in these cells (Figure S4J).
Consistent with previous results, GSK2334470 alone is not
capable of inhibiting AKT activity (Figures S4J and 3I). Therefore,
in the presence of mTOR inhibition the phosphorylation at the
HM is abrogated and this mechanism of AKT activation is no
longer supported. Addition of GSK2334470 to resistant cells
treated with AZD8055 resulted in a marked decrease in the
phosphorylation of both FOXO3 and NDRG1. This translated in
decreased cell viability in both HCC1954 and JIMT1 cells,9 (n = 27). Box indicates the median and the interquartile range, and whiskers
sitive or resistant to BYL719.
a panel of PIK3CA-mutant breast cancer cell lines. Arrowheads indicate the
r tumors and quantification of the stainings observed in a cohort of 273 breast
nd the number of patients experiencing progression of disease (POD) as best
d positivity to pNDRG1 staining by IHC.
tudy. Heatmap represents the SGK1 mRNA levels for each tumor sample.
itive and -resistant breast cancer cell lines treated with BYL719 (1 mM) for 4 hr.
SO, BYL719 (1 mM), GSK2334470 (1 mM), or the combination of both agents for
SO, BYL719 (1 mM), GSK2334470 (1 mM), or the combination of both agents for
so Figure S4.
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Figure 4. SGK1 Inhibitor Sensitizes Resistant Cells to BYL719
(A) (Left) Dose-response curves fromMDA-MB-361 cells transducedwith pLenti7.3-LacZ or pLenti7.3-SGK1 (D60, S422D) constructs and treatedwith increasing
concentrations of BYL719 for 6 days. (Right) Western blot analysis of LacZ and SGK1 transduced MDA-MB-361 cells treated with BYL719 (1 mM) for 4 hr.
(B) (Left) Growth curves of HCC1954 cells stably expressing doxycycline-inducible control (REN) or SGK1 knockdown treated with increasing concentrations of
BYL719 for 6 days. (Right) Western blot analysis of GFP-sorted control (REN) and SGK1 shRNA cells treated with BYL719 (1 mM) for 4 hr.
(C) Chemical structure of SGK1-inh and in vitro SGK1 kinase activity assay in the presence of increasing concentrations of SGK1-inh. IC50 for SGK1, SGK2, and
SGK3 are indicated.
(D) Docking overview of SGK1-inh in the DFG-out conformation of SGK1. The hinge region is colored in red, the DFGmotif in green, the ‘‘allosteric’’ hydrophobic
cavity that results from the DFG flip in grey, and the rest of the kinase in orange. The DFG motif amino acids are indicated (D240, F241, and G242).
(E) Detailed residues that mediate the interaction between SGK1-inh and the inactive conformation of SGK1. Hydrogen bonds are shown as purple dotted lines.
(F) Western blot quantification of NDRG1 phosphorylation (T346) in HCC1954 cells treated with increasing concentrations of SGK1-inh for 4 hr in the absence or
presence of BYL719 (1 mM).
(G) Western blot analysis of HCC1954 cells treated with BYL719 (1 mM), SGK1-inh (10 mM), or both agents for 4 hr.
(H) Dose-response curves from HCC1954 cells treated with BYL719 for 6 days in the absence or presence of SGK1-inh.
(I) HCC1954 xenograft treated with vehicle, BYL719 (25 mg kg1), SGK1-inh (50 mg kg1), or the combination of both agents (n = 10/arm).
(J) IHC analysis of tumors from (K) collected at the end of the experiment 4 hr after the last dosage. Scale bar, 100 mm.
p Values were calculated using Student’s t test. Error bars denote ±SEM. See also Figure S5.phenocopying the effects observed by dual PDK1 and PI3Ka in-
hibition (Figure S4K). Similar results were found when RICTOR, a
key mTORC2 component, was knocked down in the presence of
PDK1 inhibition (Figure S4L).
These results demonstrate that both PI3K and PDK1 activities
have to be suppressed to inhibit downstream AKT and SGK1
phosphorylation and activity in our resistant models.236 Cancer Cell 30, 229–242, August 8, 2016SGK1 Mediates Resistance to BYL719
We next assessed the contribution of SGK1 in mediating resis-
tance to PI3Ka inhibition. The overexpression of a constitutively
active form of SGK1 in MDA-MB-361 cells, which are sensitive
to PI3Ka inhibition, was sufficient to increase cell viability in
the presence of BYL719 (Figure 4A). In parental cells, PI3Ka
inhibition decreased both AKT phosphorylation and mTORC1
signaling, while cells overexpressing SGK1maintainedmTORC1
signaling in the presence of BYL719. Given that genetic inactiva-
tion of SGK1 is toxic (Sommer et al., 2013), we generated doxy-
cycline-inducible shRNA targeting SGK1. Upon SGK1 knock-
down we observed a decrease in cell viability that was
enhanced in the presence of BYL719 (Figure 4B). Accordingly,
SGK1 knockdown decreased pNDRG1 and mTORC1 target
levels only when combined with PI3Ka inhibition.
Next, we studied the effects of pharmacological inhibition of
SGK1 in our models. The few SGK inhibitors currently avail-
able have low activity in cellular models. To overcome this
problem, we characterized a recently described SGK inhibitor
(SGK1-inh) (Halland et al., 2015). SGK1-inh exhibited an IC50
of 4.8 nM at 10 mM ATP using a recombinant SGK1 kinase
assay, with appreciable activity also toward SGK2 and SGK3
(IC50 of 2.8 nM and 590 nM, respectively) (Figure 4C). The
specificity of this compound was tested in vitro at a concen-
tration of 1 mM (200-fold higher than the SGK1 inhibitory
dose) against a panel of 140 human kinases showing remark-
able selectivity toward SGK1 (Figure S5A). Despite detecting
no activity against AKT1, PDK1, PKC, or RSK, we found that
at this high concentration S6K was also inhibited, probably
due to the high similarity of their catalytic sites. Because
S6K is a key downstream substrate of mTORC1, we aimed
to further characterize the activity of SGK1-inh toward S6K.
Recombinant in vitro kinase assay of S6K demonstrated an
IC50 of 33 nM, seven times higher than the IC50 for SGK1 (Fig-
ure S5B). At the cellular level, we performed an S6K kinase
assay in 293T cells overexpressing constitutively active S6K
(DCT T389E) treated with increasing concentrations of
SGK1-inh, and found an IC50 of 20 mM (Figure S5C). Next,
using two fibroblast cell lines that lack TSC2 (derived from
TSC2 knockout mice and a lymphangioleiomyomatosis pa-
tient, respectively), we observed that increasing concentra-
tions of SGK1-inh up to 30 mM were not able to reduce S6K
signaling in these cellular models, as assessed by the down-
stream S6K targets pS6 (S235/6), pS6 (S240/4), and pmTOR
(S2448) (Figure S5D). This suggests that SGK1-inh does not
have activity toward S6K at concentrations below 20–30 mM.
We also excluded any potential inhibition of mTORC1 by
SGK1-inh by testing this compound against mTOR in a recom-
binant kinase assay (IC50 > 5,000 nM; Figure S5E).
Our computational analyses and preliminary characterization
of SGK1-inh suggested that this compound acts as a type II ki-
nase ATP-competitive inhibitor binding preferentially to the inac-
tive conformation of the kinase (Figure 4D). By performing an
ATP-competition assay we confirmed that addition of increasing
concentrations of ATP decreased the potency of SGK1-inh in a
dose-dependent manner (Figure S5F). Docking models using
the active conformation of SGK1 show that the sulfonamidemoi-
ety with the terminal hydrophobic ring points out from the pocket
toward the solvent (Figure S5G), rendering the bound state un-
stable. In contrast, in the inactive conformation several hydro-
phobic residues mediate interactions with SGK1-inh within the
allosteric DFG-out pocket (mainly V149, L159, V154, and V160;
Figure 4E). The pyrazolo(3,4-b)pyrazine head portion of SGK1-
inh interacts with the key residues D177 and I179, similar to
the interactions with ATP (Figures 4E and S5H). The energetics
of SGK1-SGK1-inh binding are more favorable than SGK1-ATP, as assessed by binding free energy calculations (Fig-
ure S5I). The electrostatic components of these interactions
are similar between ATP and SGK1-inh, and the majority of the
binding energy arises from more favorable packing (van der
Waals) interactions made between SGK1-inh and the kinase
(Figure S5I). Most of the favorable interactions that take place
between SGK1 and SGK1-inh are with amino acids found within
the SGK1 active site (Figure S5J, upper panel). In silico alanine
scanning of the key residues resulted in loss of binding free en-
ergies, confirming the importance of these amino acids in the
protein-ligand interactions (Figure S5J, lower panel).
Based on the ability to inhibit NDRG1 phosphorylation in the
presence of BYL719 in our models (Figure 4F), we estimated
that the appropriate concentration of SGK1-inh to fully inhibit
endogenous SGK1 is 10 mM. This relatively high concentration
(still lower than the concentration needed to affect S6K activity)
may be explained by the fact that these sulfonamide derivatives
exhibit poor permeability (133 3 107 cm s1 in Caco2 cell
permeability assays) (Halland et al., 2015). Treatment of
HCC1954 and JIMT1 cells with the combination of BYL719
and SGK1-inh not only abrogated pNDRG1 (T346) but also
mTORC1 signaling (Figures 4G and S5K). Using m7GTP pull-
downs we also found that combined PI3Ka and SGK1 inhibition
induces a decreased cap-dependent translation, as seen by the
increased 4EBP1 and decreased eIF4A and eIF4G binding to the
m7GTP beads (Figure S5L). This translated to superior inhibition
of cell viability of BYL719-resistant cell lines treated with the
combination of BYL719 and SGK1-inh (Figures 4H, S5M, and
S5N). We then assessed the potential antitumor activity of
SGK1-inh in xenografts. We observed that only the combination
of BYL719 and SGK1-inh reduced tumor burden (Figure 4I) and
phosphorylation of S6, 4EBP1, and NDRG1 (Figures 4J and
S5O).
These results show that targeting SGK1 pharmacologically is
feasible, and demonstrate that dual inhibition of AKT and
SGK1 is required to achieve full suppression of mTORC1 and
proliferation.
SGK1 Interacts with and Phosphorylates TSC2
Due to its similarity with AKT, we reasoned that SGK1 could
modulate mTORC1 activity by interacting with a component of
the TSC/RHEB/mTORC1 axis. Immunoprecipitation of TSC1,
TSC2, RHEB, and mTOR in 293T cells revealed that SGK1 phys-
ically interacts with both mTOR and TSC2 proteins (Figures 5A
and S6A). While the interaction between SGK1 and mTOR has
previously been described, as mTORC2 is responsible for the
HM phosphorylation of SGK1 (Garcia-Martinez and Alessi,
2008), to our knowledge the interaction between SGK1 and
TSC2 was previously unreported. This result was corroborated
in a live cell context by performing fluorescence resonance en-
ergy transfer (FRET) experiments using EGFP-tagged TSC2
and EYFP-tagged SGK1 in HeLa cells (Figure 5B). We further
confirmed the interaction between endogenous SGK1 and
TSC2 by co-immunoprecipitation (Figure 5C). Moreover, we
determined the proportion of endogenous SGK1 that is associ-
ated with the TSC complex by performing sucrose gradient ex-
periments in JIMT1 lysates. The TSC complex fractionated at
high-density fractions (fraction 5), as assessed by the presence
of the three components TSC1, TSC2, and TBC1D7 (Figure S6B)Cancer Cell 30, 229–242, August 8, 2016 237
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Figure 5. SGK1 Interacts with and Phosphorylates TSC2
(A) Co-immunoprecipitation assay in 293T cells ectopically express the indicated proteins.
(B) Representative efficiency images from the FRET experiment performed in HeLa cells, with the constructs indicated above. Scale bar, 5 mm. Quantification of
FRET efficiency dots is shown on the right. ROI, region of interest.
(C) Co-immunoprecipitation (IP) of endogenous SGK1 and TSC2 in JIMT1 cells. IgG, immunoglobulin G.
(D) Co-immunoprecipitation assay in 293T cells between FLAG-SGK1 and truncation mutants of HA-TSC2. Asterisk indicates IgG. Truncation TSC2 mutants are
shown schematically at the top. Domains: LZ, leucine zipper; CC, coiled coil; GAP, GTPase activation protein.
(E) In vitro kinase assay using recombinant His-SGK1 and immunoprecipitated FLAG-TSC2 from 293T cells as a substrate (2 mM MK2206, 1 hr).
(F) Quantification of the phosphorylated site identified using liquid chromatography-MS/MS in the absence or presence of recombinant SGK1. Schematic view
and amino acid sequence of the predicted SGK1 phosphorylation sites in TSC2 are shown at the top.
(G) In vitro kinase assay using recombinant His-SGK1 and immunoprecipitated and dephosphorylated FLAG-TSC2 WT or 6A as a substrate.
(H) Western blot of phosphorylated TSC2 (S939) in HCC1954 and JIMT1 cells treated with DMSO, BYL719 (1 mM), GSK2334470 (1 mM), SGK1-inh (10 mM), or the
combination of both agents for 4 hr.
p Values were calculated using Student’s t test. Error bars denote ±SEM. See also Figure S6.(Dibble et al., 2012). Although most of the SGK1 fractionated at
low-molarity fractions, approximately 20% of the kinase eluted
at fractions similar to those of the TSC complex. Considering
SGK1 as a monomer (or perhaps a dimer [Zhao et al., 2007]),
only the association with a larger complex such as the TSC com-
plex can explain the elution at these high sucrose gradients.
Co-immunoprecipitation assays using five different fragments
of TSC2 demonstrated that SGK1 binds to the N-terminal region
of TSC2 (Figure 5D), which contains a leucine zipper (LZ) domain
important for protein-protein interactions and the interactionwith
TSC1 (Li et al., 2004).
SGK1 has high similarity to AKT in the kinase domain and thus
shares many substrates that contain the AGC kinase consensus
motif RXRXX(S/T), where R is arginine, X is any amino acid, and
(S/T) is a phosphorylatable serine or threonine (Alessi et al.,
2009). The use of a degenerated phosphospecific motif antibody238 Cancer Cell 30, 229–242, August 8, 2016allows detection of these phosphosites and has previously been
shown to be a reliable surrogate for phospho-TSC2 detection
(Manning et al., 2002). When we analyzed the TSC2 protein
sequence we found seven putative sites of phosphorylation:
S939, S981, T993, S1130, S1132, T1462, and S1798. All of these
sites were conserved across several species (Figure S6C). We
then established an in vitro kinase assay using recombinant
active SGK1 and TSC2 immunoprecipitated from 293T cells as
a substrate. To deplete endogenous phosphorylated TSC2, we
pre-treated 293T cells with the AKT inhibitor MK2206. The addi-
tion of recombinant SGK1 kinase increased the phosphorylation
of the RXRXX(S/T) sites of TSC2, even when cells were pre-
treated with AKT inhibitor (Figure 5E). Using mass spectrometry
(MS), we found increased phosphorylation in all of these sites,
except for T993 (Figure 5F). Mutation of these six sites into the
non-phosphorylatable amino acid alanine (TSC2 6A) completely
Figure 6. Proposed Model of PI3Ka Resistance in SGK1-Expressing Cells
PIK3CA-mutant breast tumors depend on the PI3K pathway, which mainly signals through AKT. AKT phosphorylates and inhibits FOXO3 and TSC2, promoting
mTORC1 activity and tumor progression (left panel). In the presence of PI3Ka inhibitors, PIP3 levels in the plasma membrane are negligible and AKT cannot be
activated. High SGK1 cells become resistant to PI3Ka inhibitors, as SGK1 is not fully inhibited in the presence of these therapies, supporting FOXO3 and TSC2
phosphorylation, which promotes mTORC1 activity and tumor progression (middle panel). When SGK1 expressing cells are treated with PI3Ka and PDK1 in-
hibitors, both AKT and SGK1 are inhibited, inducing tumor regression as a result of FOXO3 activation and mTORC1 inhibition (right panel).abrogated the ability of SGK1 to phosphorylate TSC2 in vitro
(Figure 5G).
It is well accepted that phosphorylation of these sites in-
creases downstream RHEB-GTP loading and mTORC1 sig-
naling, as a result of a translocation from the lysosome to the
cytoplasm (Inoki et al., 2003a; Menon et al., 2014). The phos-
phorylation and inhibition of TSC2 is phenocopied by the loss
of expression of the protein itself, as demonstrated by the in-
duction of mTORC1 activity and consequent resistance to
BYL719 in the T47D PI3Ka inhibitor-sensitive cell line depleted
of TSC2 (Figures S6D and S6E). To confirm that our biochem-
ical findings are consistent with the proposed mechanism of
resistance to BYL719, we treated HCC1954 and JIMT1 cells
with BYL719, GSK2334470, SGK1-inh, and the combination
of these agents, and found that the phosphorylation of endog-
enous TSC2 decreases only upon dual PI3Ka and PDK1 or
SGK1 suppression (Figure 5H). These results demonstrate
that SGK1 can sustain mTORC1 activity in BYL719-resistant
cells by phosphorylating and inhibiting the mTORC1-negative
regulator TSC2.
We then asked whether kinases other than AKT or SGK1 are
involved in the phosphorylation of TSC2 and sustained activation
of mTORC1 upon PI3Ka inhibition (Figure S6F). Extracellular
Signal-regulated Kinase (ERK) and the downstream AGC kinase
RSK phosphorylate TSC2, activating downstream mTORC1 ef-
fectors (Ma et al., 2005; Roux et al., 2004). However, we did
not detect changes in TSC2 phosphorylation at S939 (or
mTORC1 downstream signaling) when HCC1954 cells were
treated with the MEK inhibitors PD0325901 and GSK1120212,
and downstream ERK and RSK were fully inhibited (Figure S6G).AMP-dependent protein kinase (AMPK), which is activated in
conditions of energy stress, phosphorylates TSC2 at S1345
and induces the inhibition of mTORC1 (Inoki et al., 2003b). Treat-
ment of HCC1954 cells with the stress-inducing agent 2-deoxy-
glucose and the AMPK activator A769662 were unable to rescue
the sustained phosphorylation of S6 in this resistant model (Fig-
ure S6H). In line with the AMPK regulation of mTORC1 signaling,
GSK3 kinase has also been reported to phosphorylate TSC2 us-
ing the AMPK-specific site S1345 as a priming event, in a pro-
cess downstream of WNT signaling (Inoki et al., 2006). However,
incubation of HCC1954 cells with the recombinant WNT antago-
nist DKK-1 did not reduce the sustained S6 phosphorylation
(Figure S6I).
Altogether, these results suggest that in our resistant models
SGK1 is the main kinase involved in the phosphorylation of
TSC2 and sustained mTORC1 activation.
DISCUSSION
In this work, we show that inhibition of the constitutively active
kinase PDK1 overcomes resistance to PI3Ka inhibitors in
PIK3CA-mutant breast cancer cells insensitive to PI3Ka inhibi-
tion. We discovered that upon PI3Ka inhibition, and thus low
levels of PIP3 and full suppression of AKT, SGK1 contributes to
the maintenance of residual mTORC1 activity and cell survival
through direct phosphorylation and inhibition of TSC2. Suppres-
sion of either PDK1 or SGK1 prevents mTORC1 activation and
sensitizes resistant cells to PI3Ka blockade, underscoring the
causative role of this signaling route in inducing the resistance
phenotype (Figure 6).Cancer Cell 30, 229–242, August 8, 2016 239
Summarizing our current knowledge, resistance to PI3Ka in-
hibitors in PIK3CA-mutant malignancies may occur as a result
of either PI3K-dependent or -independent mechanisms. An
example of a PI3K-dependent acquired resistance mechanism
has recently been shown by the observation that loss of PTEN re-
sults in activation of PI3K p110b, thus forfeiting PI3Ka signaling
(Juric et al., 2015). Similarly, reactivation of PI3K p110b signaling
has also been revealed to be a mechanism of adaptive resis-
tance in PI3Ka-driven cells (Costa et al., 2015). In terms of
PI3K-independent mechanisms, we now propose that mTORC1
sustained activity is, at least in part, mediated by PDK1-SGK1
signaling. In this context, AKT activity would be dispensable
for cell survival, in accordance with previous reports showing
that AKT activity is not always required for the downstream
PI3K signaling (Gasser et al., 2014; Vasudevan et al., 2009).
The role of SGK1 in mediating mTORC1 activation upon PI3Ka
inhibition can be explained by the differential regulation of AKT
and SGK1 upon pharmacological stress. Although both kinases
share the same upstream regulators, mTORC2 and PDK1, AKT
contains a PH domain that is required for the PI3K-dependent
plasma membrane translocation and subsequent activation. In
contrast, SGK1 does not require plasma membrane localization,
which could partially explain why it remains active in the absence
of PIP3. In our resistant cell lines treated with PI3Ka inhibitor, we
observe a substantial but incomplete decrease in SGK1 activity.
This can be partially explained by the fact that PIP3 controls
mTORC2 (Gan et al., 2011) in a mechanism that seems to require
mSIN1 (Liu et al., 2015). However, other PIP3-independent pools
of mTORC2 that are not regulated by growth factors (Frias et al.,
2006) might be responsible for residual SGK1 activity. While
PDK1 is a constitutively active kinase and can be present in
both cytoplasm and membrane (upon PIP3 synthesis), the sub-
cellular localization of mTORC2 is ambiguous (Cybulski and
Hall, 2009). Therefore, it is plausible that different pools of
mTORC2 can be found within the cell.
Pharmacological inhibitionofPDK1hasbeen reported tohavea
profound effect on the activity of several AGC kinases such as
RSK, S6K, PKC, and SGK (Najafov et al., 2011). However, higher
doses of PDK1 inhibitors are required to achieve the same inhibi-
tory effects on AKT. In fact, in the presence of 1 mMGSK2334470
AKT can be efficiently activated by PDK1 through different PIP3-
dependent or PIF-binding pocket-dependent mechanisms (Naja-
fov et al., 2012). In our experiments using endogenous immuno-
precipitated SGK1 and AKT, we show that this is indeed the
case. In the presence of BYL719, SGK1 but not AKT remains
active; conversely, upon GSK2334470 treatment, SGK1 but not
AKT is fully inhibited. Single activity of any of these kinases seems
to be sufficient to propagate downstream pro-survival signaling
through mTORC1 activation and FOXO3 repression. This is also
confirmed by the fact that the combination of both agents effi-
ciently inhibitsFOXO3andmTORC1,elicitingapowerful antitumor
effect. In this setting, rather than inhibition of AKT, NDRG1 phos-
phorylation (a substrate of both AKT and SGK1) should be used
as readout of pathway inhibition (Kobayashi et al., 1999).
The role of SGK1 in regulating signaling downstream of
mTORC2 is intriguing but not entirely unexpected. From the
evolutionary point of view, the SGK1 ortholog in Drosophila mel-
anogaster is dAkt, which shares similarity with human SGK1
(63%) and AKT1 (67%). Thus, it is tempting to speculate that240 Cancer Cell 30, 229–242, August 8, 2016due to the high overlap of their substrates, Drosophila dAkt
plays the role of both AKT and SGK1. In fact, Ypk2 and Gad8,
the SGK1 orthologs in budding and fission yeast, respectively,
are the main TORC2 downstream effectors (Cybulski and
Hall, 2009; Kamada et al., 2005; Matsuo et al., 2003). Similarly,
in Caenorhabditis elegans, sgk-1 appears to be essential for
TORC2 signaling, lifespan, and growth (Jones et al., 2009; Sou-
kas et al., 2009).
In summary, our findings show that SGK1mediates resistance
to PI3Ka inhibitors through the activation of mTORC1, which can
be reverted by PDK1 blockade. This study highlights the impor-
tance of understanding the underlying mechanisms of protein ki-
nase regulation in uncovering critical nodes for pharmacological
intervention and improving the therapeutic options for onco-
gene-driven cancers.
EXPERIMENTAL PROCEDURES
RNAi Screening
JIMT1 and HCC1954 cells were seeded and reverse transfected using Dhar-
mafect-1 with the kinome and phosphatome Ambion Silencer Select v4.0
libraries. Cells were treated with DMSO or 1 mM BYL719, and 7 days after
transfection cell viability was assessed. Full details can be found in Supple-
mental Experimental Procedures.
Immunoblot Detection
Protein lysates were extracted and separated using SDS-PAGE gels accord-
ing to standard methods. Membranes were probed using specific antibodies.
PDK1, pAKT (S473), pAKT (T308), pS6K (T389), pS6 (S240/4), pS6 (235/6),
p4EBP1 (S65), PARP, Actin, pRSK (S227), cleaved caspase 3, pFOXO1/3
(T24/T32), SGK1, SGK2, SGK3, pNDRG1 (T346), NDRG1, FLAG, HA, and
phospho-RXRXX(S/T) were from Cell Signaling Technology.
Animal Studies
Animals were housed, maintained, and treated at Memorial Sloan Kettering
Cancer Center (MSKCC) in accordance with Institutional Animal Care and
Use Committee (protocol number 12-10-019). 5 3 106 cells in 1:1 PBS/Matri-
gel (Corning) were injected subcutaneously into athymic Foxn1nu nude mice.
When a volume of150mm3was reachedmice were randomized and treated,
and tumors were measured twice per week for 1 month. Full details can be
found in Supplemental Experimental Procedures.
Patient Samples
The MSKCC Institutional Review Board approved the study. Pre-treatment
formalin-fixed paraffin-embedded blocks from patients treated with the
PI3Ka inhibitor BYL719 enrolled in the clinical trial NCT01870505 conducted
at MSKCC were used for immunohistochemistry (IHC). Informed consent
was obtained from all subjects. Full details of tissue microarray construction
are provided in Supplemental Experimental Procedures.
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